Figure 2. miR-375-3p inhibits proliferation, chemoresistance and promotes 5FU-induced apoptosis of CRC cells in vitro. (A) Cell proliferation was detected by MTT assay after different concentrations of transfection together with 5FU treatment or not. (Left : HCT116/FU cells transfected with miR-375-3p/NC mimics: 25nM and 50nM; Right : HCT116 cells transfected with miR-375-3p/NC inhibitors : 50nM and 100nM). (B, C) HCT116/FU and HCT116 cells were respectively transfected with miR-375-3p mimics or inhibitors together with 5FU treatment or not. Colony formation assay were measured to show miR-375-3p inhibited cell growth. (D) MTT assay showed overexpression of miR-375-3p increased the sensitivity of HCT116/FU cell lines to 5FU and inhibition of miR-375-3p enhanced the resistance of HCT116 cell lines to 5FU. (E) The sensitivity of HCT116/FU(Left) and HCT116(Right) cells to multiple anticancer drugs were measured after transfection. (No transfection of HCT116/FU and HCT116 cell lines were taken as 100% viability, respectively; HCT116/FU cells: oxaliplatin 15μg/ml, irinotecan: 100μg/ml, capecitabine: 40μg/ml; HCT116 cells: oxaliplatin 2.5μg/ml, irinotecan: 18μg/ml, capecitabine: 4μg/ml;). (F) The sensitivity of DLD1, HT29 and SW620 CRC cell lines to 5FU were measured after transfection. (No transfection of cell lines were taken as 100% viability, respectively). (G) The apoptotic rate of the indicated cells transfected with miR-375-3p mimics or inhibitors, respectively, together with different concentrations of 5FU treatment were detected by flow cytometry analysis. (Left: HCT116/FU cells, concentration groups of 5FU: 150μg/ml and 200μg/ml; Right: HCT116 cells, concentration groups of 5FU: 10μg/ml and 25μg/ml). * P < 0.05, ** P < 0.01 and *** P < 0.001.